Tenet Healthcare (NYSE:THC) Stock Rating Lowered by Wall Street Zen

Tenet Healthcare (NYSE:THC) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. raised their price target on Tenet Healthcare from $200.00 to $230.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Zacks Research lowered shares of Tenet Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Cantor Fitzgerald increased their price target on shares of Tenet Healthcare from $190.00 to $245.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Royal Bank Of Canada increased their target price on Tenet Healthcare from $230.00 to $252.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Finally, Wells Fargo & Company lifted their price target on Tenet Healthcare from $238.00 to $252.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Tenet Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $231.81.

Tenet Healthcare Price Performance

THC stock opened at $200.45 on Friday. The stock has a market capitalization of $17.62 billion, a price-to-earnings ratio of 13.74, a PEG ratio of 0.86 and a beta of 1.44. The firm’s 50-day moving average price is $203.22 and its two-hundred day moving average price is $187.24. The company has a current ratio of 1.71, a quick ratio of 1.64 and a debt-to-equity ratio of 2.27. Tenet Healthcare has a 12-month low of $109.82 and a 12-month high of $222.82.

Tenet Healthcare (NYSE:THC) last posted its earnings results on Tuesday, October 28th. The company reported $3.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.33 by $0.37. Tenet Healthcare had a return on equity of 25.11% and a net margin of 6.49%.The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.26 billion. During the same period last year, the firm earned $2.93 earnings per share. Tenet Healthcare’s quarterly revenue was up 3.2% on a year-over-year basis. Tenet Healthcare has set its FY 2025 guidance at 15.930-16.26 EPS. As a group, equities analysts predict that Tenet Healthcare will post 12.24 earnings per share for the current year.

Insider Activity

In related news, Director Tammy Romo sold 645 shares of the business’s stock in a transaction that occurred on Wednesday, November 5th. The shares were sold at an average price of $205.20, for a total value of $132,354.00. Following the completion of the transaction, the director directly owned 34,866 shares in the company, valued at $7,154,503.20. The trade was a 1.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nadja West sold 2,178 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $197.47, for a total value of $430,089.66. Following the sale, the director owned 28,480 shares in the company, valued at approximately $5,623,945.60. This represents a 7.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 45,500 shares of company stock valued at $9,247,071. Company insiders own 0.81% of the company’s stock.

Institutional Investors Weigh In On Tenet Healthcare

Large investors have recently bought and sold shares of the business. Norges Bank bought a new position in Tenet Healthcare during the 2nd quarter valued at about $206,981,000. Eminence Capital LP purchased a new position in shares of Tenet Healthcare during the third quarter valued at approximately $225,263,000. Boston Partners boosted its holdings in Tenet Healthcare by 95.0% in the second quarter. Boston Partners now owns 2,267,142 shares of the company’s stock worth $398,949,000 after purchasing an additional 1,104,500 shares during the last quarter. AQR Capital Management LLC raised its stake in Tenet Healthcare by 62.3% during the 3rd quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock valued at $380,989,000 after buying an additional 720,160 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in shares of Tenet Healthcare by 375.7% during the 2nd quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock valued at $139,085,000 after buying an additional 624,125 shares during the period. 95.44% of the stock is currently owned by institutional investors.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.